Remifentanil Plus Ketamine for Dynamic Flexible Bronchoscopy
NCT03613792
Withdrawn
This randomized controlled pilot clinical trial will enroll patients undergoing dynamic flexible bronchoscopy will be randomized to receive one of the two anesthetic combinations described above. The study will determine if there is a difference when considering patient and physician and satisfaction when performing DFB. Also, safety and efficacy of the two pharmacological combinations (fentanyl + midazolam and remifentanil + ketamine) used will be evaluated.
Gender:
ALL
Ages:
19 years and above
Trial Updated:
07/25/2023
Locations: Beth Israel Deaconess Medical Center (BIDMC), Boston, Massachusetts
Conditions: Bronchoscopy
Register for Updates
Reversal of Battle-Related Aging (ROBRA) in a Special Operations Forces Cohort
NCT05855876
Recruiting
The purpose of this study is to examine measures of GrimAge clock in SOF members undergoing treatment for PTSD/TBI using CSB.
Gender:
ALL
Ages:
Between 40 years and 60 years
Trial Updated:
07/13/2023
Locations: Stella Center, Westmont, Illinois
Conditions: Post-Traumatic Stress Disorder, Traumatic Brain Injury
Register for Updates
Ketamine and Morphine Versus Morphine Alone for the Treatment of Acute Pain in the Emergency Department
NCT01900847
Terminated
Our goal is to study whether giving people low dose ketamine along with morphine when they come to the Emergency Department will help their pain more than giving morphine by itself. There have been many studies showing that low dose ketamine is safe and effective for pain control. Ketamine is frequently used for pain control in ambulances and helicopters transporting injured patients to the hospital and has also been used for pain control in people who have just had surgery. The investigators wo... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
07/11/2023
Locations: University of Arizona Health Network University Campus 1501 North Campbell Ave, Tucson, Arizona
Conditions: Acute Pain
Register for Updates
Low-Dose Ketamine in Children With ADNP Syndrome
NCT04388774
Completed
This is a Phase 2A, single dose, open-label study to evaluate the safety, tolerability, and efficacy of a low-dose, 40-minute infusion into the veins (intravenous infusion or "IV") of ketamine in children with ADNP syndrome (Activity-Dependent Neuroprotective Protein). The study team will enroll 10 participants, ages 5 to 12, at Mount Sinai. The study participation is expected to last 4 weeks and will include 5 scheduled clinic visits in order to complete safety monitoring, clinical assessments,... Read More
Gender:
ALL
Ages:
Between 5 years and 12 years
Trial Updated:
07/05/2023
Locations: Icahn School of Medicine at Mount Sinai, New York, New York
Conditions: ADNP Syndrome
Register for Updates
Ketamine in Borderline Personality Disorder
NCT03395314
Terminated
The purpose of this study is to test the potential of the rapid-acting anti-depressant ketamine to decrease suicidality in Borderline Personality Disorder (BPD). The rate of completed suicide in BPD is similar to that of depression or schizophrenia. There is currently no specific medication treatment for BPD. Ketamine is an FDA-approved anesthetic agent that has been shown to rapidly decrease suicidality and improve mood in people with Major Depressive Disorder (MDD). Though symptoms overlap,... Read More
Gender:
ALL
Ages:
Between 21 years and 60 years
Trial Updated:
05/31/2023
Locations: Connecticut Mental Health Center, New Haven, Connecticut +1 locations
Conditions: Borderline Personality Disorder
Register for Updates
Ketamine for Pain in the Emergency Department
NCT03896230
Terminated
This study will prospectively compare the mean Numerical Rating Scale (NRS) pain score reduction amongst three recommended dosing strategies of intravenous ketamine (0.1 mg/kg, 0.2 mg/kg, and 0.3mg/kg) for acute pain in the emergency department (ED).This study will also examine the frequency of adverse events secondary to ketamine including fatigue, dizziness, nausea, headache, feeling of unreality, changes in hearing or vision, mood changes, generalized discomfort, and hallucinations, changes i... Read More
Gender:
ALL
Ages:
21 years and above
Trial Updated:
05/11/2023
Locations: Hackensack University Medical Center, Hackensack, New Jersey
Conditions: Acute Pain
Register for Updates
Intraoperative Methadone Administration for Improved Pain Control in Spinal Fusion Patients
NCT02989597
Terminated
Methadone has several advantages over standard narcotic medications, especially when considering use after a typically painful surgery such as lumbar fusion. Methadone is low cost, has a long half-life, has a convenient dosing schedule, has excellent oral bioavailability, and demonstrates slow onset to withdrawal. The literature comparing methadone to more commonly used post-operative narcotics demonstrates that it manages pain better, sustains consistent plasma concentrations, decreases overall... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/24/2023
Locations: Montefiore Medical Center, Bronx, New York
Conditions: Pain, Postoperative
Register for Updates
Effect of Postoperative Single Dose of Ketamine on Pain After Mastectomy
NCT04831736
Completed
This is a randomized, single blinded, placebo-controlled trial to study the effectiveness of a subanesthetic dose (0.6mg/kg) of ketamine versus placebo (saline) on postoperative pain on adult women undergoing mastectomy. The objective of the study is to examine the effect of a subanesthetic dose (0.6mg/kg) of ketamine vs. saline control on postoperative pain in subjects who have undergone mastectomy.
Gender:
FEMALE
Ages:
Between 18 years and 80 years
Trial Updated:
04/24/2023
Locations: NYU Langone Health, New York, New York
Conditions: Postoperative Pain
Register for Updates
Intranasal Ketamine for Anxiolysis in Pediatric Emergency Department Patients
NCT03043430
Terminated
Investigators plan to conduct a randomized, double-blinded, controlled study among pediatric patients requiring minor procedures in the Emergency Department setting. Patients will be randomized to one of two arms of intranasal treatments: ketamine 1.0 mg/kg (K) or midazolam 0.3 mg/kg (M). The primary outcome will be change in anxiety using the Modified Yale Preoperative Anxiety Scale (mYPAS).
Gender:
ALL
Ages:
Between 2 years and 12 years
Trial Updated:
04/23/2023
Locations: San Antonio Military Medical Center, Fort Sam Houston, Texas
Conditions: Anxiety, Pediatric ALL, Procedural Anxiety
Register for Updates
Intranasal Versus Intravenous Ketamine for Procedural Sedation in Children With Non-operative Fractures
NCT03781817
Terminated
This a randomized clinical trial involving children with non-operative fractures presenting the emergency department randomized either to intranasal or intravenous ketamine.
Gender:
ALL
Ages:
Between 1 year and 18 years
Trial Updated:
04/19/2023
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Trauma, Fractures, Closed, Children, Only, Deep Sedation, Ketamine
Register for Updates
UNderstanding CONSciousness Connectedness and Intraoperative Unresponsiveness Study
NCT03284307
Completed
This study will be a single-site, controlled, unblinded study at the University of Wisconsin to examine changes in the electroencephalogram during anesthesia and waking.
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
04/10/2023
Locations: UW Hospital and Clinics, Madison, Wisconsin
Conditions: Unconsciousness, Consciousness
Register for Updates
Ketamine for Severe Adolescent Depression: Intermediate-term Safety and Efficacy
NCT03889756
Terminated
The purpose of this study is to evaluate the intermediate-term efficacy and tolerability of a multiple-dosing ketamine infusion paradigm for the treatment of medication-refractory major depressive disorder (MDD). We are using a two-phase design. The first phase is a 3-week double blind parallel design clinical trial comparing 6 infusions of ketamine compared to 6 infusions of midazolam in 24 adolescents with treatment resistant depression. The primary outcome of this phase will be Children's Dep... Read More
Gender:
ALL
Ages:
Between 13 years and 17 years
Trial Updated:
03/31/2023
Locations: Yale Child Study Center, New Haven, Connecticut
Conditions: Major Depressive Disorder
Register for Updates